NCT06983665已完成不适用
Single-Dose, Randomized, Open-Label, Two-Sequence, Two-Period, Double-Crossover, Bioequivalence Study of Liposomal Amphotericin B for Injection in Healthy Chinese Subjects
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 58
- 试验地点
- 1
- 主要终点
- Bioequivalence based on Cmax of liposome-encapsulated
研究概览
简要总结
A single-center, randomized, open-label, single-dose, two-period, double-crossover study to evaluate the bioequivalence of liposomal amphotericin B for injection (test product) manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd. compared to the reference product (AmBisome®) in healthy Chinese subjects. Secondary objectives include safety evaluation.
详细描述
The study involves 42 healthy subjects (male and female) aged 18-55 years. Subjects will be randomized into two groups (TR and RT) and receive either the test or reference product in period 1, followed by a 92-day washout period before crossing over to the other product in period 2. Blood samples will be collected at 25 time points for pharmacokinetic analysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Open-label
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntary participate in the clinical trial, with the ability to sign an informed consent form (ICF) and have a full understanding of trial contents, process, and potential adverse reactions, and be able to understand and adhere to the trial procedures;
- •Chinese male and female subjects aged 18 to 55 years old (inclusive);
- •Male subjects with weight no less than 50.0 kg, and female subjects with weight no less than 45.0 kg. Body mass index (BMI) = weight/height2 (kg/m2). BMI is 18.6-28.5 kg/m2 (both inclusive);
- •At screening, subjects' vital signs, physical examinations, laboratory tests, and electrocardiogram (ECG) results are normal, or abnormal but clinically insignificant as determined by the Investigator;
- •Subjects (including male subjects) have adopted effective contraceptive measures within 14 days prior to the first dosing and are willing to refrain from pregnancy, donating sperm or eggs, and voluntarily use effective contraceptive measures (non-pharmacological contraception during the trial) from the time of signing the informed consent form until 6 months after the last dose.
排除标准
- •Subjects with chronic or severe diseases of the cardiovascular, hepatic, renal, respiratory, hematological and lymphatic, endocrine, immune, mental and nervous, gastrointestinal, metabolic, and skeletal systems, who, as determined by the Investigator, are not suitable to participate in the study;
- •Subjects with clinically significant abnormalities as determined by the Investigator, including physical examination, vital signs, ECG or clinical laboratory tests, especially abnormalities in hepatic and renal functions (subjects with serum creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) above the upper limit of normal (ULN));
- •Subjects with existing allergic diseases (nettle rash, eczema, etc.), or an atopic constitution (e.g. allergies to two or more medications, foods such as milk, or pollen), or a known history of hypersensitivity to any component of conventional amphotericin B formulations or liposomal amphotericin B formulations, including the active ingredient or any excipients in this product (such as soybean oil), peanuts or soy;
- •Subjects who are positive for any one or more of the following tests: Hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody, Treponema pallidum specific antibody and human immunodeficiency virus (HIV) antigen/antibody;
- •Subjects with a history of drug abuse;
- •Subjects who are positive for urine drug screening (methamphetamine (meth), MDMA (ecstasy), THC (cannabis), morphine, ketamine);
- •Regular drinkers within 3 months prior to screening, defined as subjects who drink more than 14 units of alcohol per week (1 unit ≈ 285 mL of beer with 3.5% ABV or 25 mL of spirits with 40% ABV or 85 mL of wine with 10% ABV), or subjects who cannot stop drinking or consuming any alcoholic products throughout the study;
- •Subjects who are positive for breath alcohol test;
- •Subjects with excessive daily consumption of tea, coffee, and/or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) within the 3 months prior to screening;
- •Subjects with a daily cigarette consumption of > 5 cigarettes/day within 3 months prior to screening, or who cannot discontinue any tobacco-based products, nicotine products, or e-cigarette products throughout the study;
- •Subjects with a history of surgery within 3 months prior to screening, or planned surgery, dental procedures, or hospitalization during the study period;
- •Subjects who have donated blood or experienced massive blood loss (> 400 mL) within 3 months prior to screening, or donated platelets ≥2 therapeutic doses (1 therapeutic dose = 12 U of platelets) within 1 month prior to screening;
- •Subjects who have participated in and received treatment in any drug or medical device clinical study within 3 months prior to screening;
- •Subjects who have received any live vaccine within 3 months prior to screening, or any COVID-19 vaccine within 2 weeks prior to screening, or who are scheduled to be vaccinated within one month after study completion;
- •Subjects who have used any oral contraceptives within 30 days prior to screening or any long-acting estrogen and/or progestin injections and/or implantable contraceptive devices within 6 months prior to screening;
- •Subjects who have used any medications within 28 days prior to screening that affect the absorption and metabolism of the investigational drug (including hepatic enzyme inhibitors, inducers, or those that alter the gastrointestinal environment), or interact with the investigational drug (e.g., corticosteroids, adrenocorticotropic hormone drugs, pyrrolizidine drugs (e.g., ketoconazole, miconazole, clotrimazole, fluconazole), skeletal muscle relaxants, antineoplastic agents, digitalis glycosides, flucytosine, or other nephrotoxic drugs), and who, as determined by the Investigator, are not suitable to participate in the study;
- •Subjects who have used any prescription drugs within 14 days prior to screening or any over-the-counter drugs, Chinese herbal medicines or health products within 7 days prior to screening, except for topical drugs that act on a particular place of body;
- •Subjects who are unable to avoid consuming xanthine-rich beverages (coffee, tea, etc.) or foods (chocolate, animal liver, etc.), or consuming fruits or juices that may affect metabolism (grapefruit, pomelo, mango, dragon fruit, etc.) or iodine-rich foods (seaweed, kelp, etc.) during a period from 48 hours pre-dose to the end of the study, or subjects who have other factors that affect drug absorption, distribution, metabolism and excretion;
- •Subjects who have taken strenuous exercise within 48 hours prior to screening;
- •Subjects who have special requirements for diet and cannot follow the diet provided during the study;
- •Subjects who have difficulty in venous blood collection or a history of fear of needles or hemophobia;
- •Female subjects who are breastfeeding or have a positive pregnancy test result during the screening period or course of the trial;
- •Subjects who, as determined by the Investigator, are not suitable to participate in the study.
研究组 & 干预措施
Group I, Liposomal amphotericin B for injection
Experimental
Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.)
干预措施: Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.) (Drug)
Group II, AmBisome®
Experimental
Reference product (AmBisome®, Astellas Pharma US Inc.)
干预措施: Reference product (AmBisome®, Astellas Pharma US Inc.) (Drug)
结局指标
主要结局
Bioequivalence based on Cmax of liposome-encapsulated
时间窗: 0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose
90% Cl of Cmax of liposome-encapsulated amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%\~125.00%
Bioequivalence based on AUC0-t of liposome-encapsulated
时间窗: 0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose
90% Cl of AUC0-t of liposome-encapsulated amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%\~125.00% amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%\~125.00%
Bioequivalence based on AUC0-∞ of liposome-encapsulated
时间窗: 0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose
90% Cl of AUC0-∞ of liposome-encapsulated amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%\~125.00% amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%\~125.00% amphotericin B between Amphotericin B liposome for injection and AmBisome® within 80.00%\~125.00%
次要结局
- AUC0-t of free amphotericin B(0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose)
- Partial exposure indicators (AUC24-last) of free amphotericin B(24 hours post formal dose to 1320 hours post formal dose)
- AUC%Extrap(0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose)
- AUC0-∞ of free amphotericin B(0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose)
- Partial exposure indicators (AUC0-24h)(0 h before safe dose and 0 h before formal dose to 24 hours post formal dose)
- Tmax(0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose)
- t1/2(0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose)
- λz(0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose)
- Cmax of free amphotericin B(0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose)
- Partial exposure indicators (AUC0-10h) of liposome-encapsulated amphotericin B(0 h before safe dose and 0 h before formal dose to 10 hours post formal dose)
- F(0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose)
- Partial exposure indicators (AUC10-last) of liposome-encapsulated amphotericin B(10 hours post formal dose to 1320 hours post formal dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed ConditionsBioequivalenceNCT04689919University of Karachi26
撤回
1 期
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast CancerLocally Recurrent CancerMetastatic Breast CancerNCT04332549Sun Pharma Advanced Research Company Limited
已完成
不适用
Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy VolunteersChronic Hepatitis bNCT03847246Chia Tai Tianqing Pharmaceutical Group Co., Ltd.26
已完成
1 期
Safety and Pharmacokinetic Characteristics of DKF-313Benign Prostate HyperplasiaHealthyNCT02352311Dongkook Pharmaceutical Co., Ltd.54
Unknown
1 期
Pharmacokinetic Assessment of Simultaneous Administration of Clopidogrel and AspirinCoronary Artery DiseaseNCT01388660Ajou University School of Medicine60